About NeoBiotechnologies
Founded in 2013, NeoBiotechnologies develops monoclonal, recombinant and polyclonal antibodies for biomedical research, with a particular focus on cancer biology, immuno-oncology, pathology and translational research. The company combines antibody discovery, hybridoma development and recombinant engineering with extensive validation workflows designed to assess specificity, affinity and cross-reactivity. A notable component of its validation strategy is the use of HuProt™ human protein arrays, which enable screening against large numbers of human proteins to support reliable target identification and biomarker studies. Its technologies support applications including immunohistochemistry (IHC), immunofluorescence, western blotting, ELISA and flow cytometry, helping researchers investigate protein expression, disease mechanisms and clinically relevant biomarkers.
The company’s portfolio includes thousands of monoclonal antibodies, recombinant antibodies, rabbit monoclonals and HuProt™-validated antibodies covering a broad range of molecular targets. Products are developed for use in oncology, immunology, infectious disease, neuroscience and other areas of life science research, with formats suitable for tissue-based analysis, biomarker discovery and assay development. NeoBiotechnologies also provides licensing opportunities for diagnostic, therapeutic and companion diagnostic applications.
Europa Biosite subsidiaries distribute NeoBiotechnology products in Austria, Belgium, Canada, Denmark, Estonia, Finland, Germany, Iceland, Ireland, Latvia, Lithuania, Luxemburg, Netherlands, Norway, Sweden, Switzerland, United Kingdom and the USA.